Core Insights - The company aims to transform into a biopharmaceutical enterprise by focusing on clinical needs and leveraging its expertise in apoptosis pathways and innovative drug development [2][4] Company Overview - Established in 2009, the company specializes in developing innovative drugs for unmet clinical needs in oncology, with a strong pipeline including key products like APG-3288, a next-generation BTK-targeted protein degrader [2][4] - The company has successfully launched two major Class 1 new drugs: Nairike, approved in 2021, and Lishengtuo, expected to be approved in July 2025 [2][3] Product Highlights - Lishengtuo breaks the nine-year monopoly of AbbVie’s Bcl-2 inhibitor Venetoclax, representing a significant achievement after 21 years of development [3][4] - Nairike addresses limitations of first and second-generation treatments for chronic myeloid leukemia, filling a domestic treatment gap [4][10] Clinical Development - The company is conducting over 40 clinical trials globally, including three global Phase III studies for Nairike and four for Lishengtuo, with significant milestones achieved in regulatory approvals [6][7] - Lishengtuo is the only Bcl-2 inhibitor currently advancing in Phase III trials for high-risk myelodysplastic syndromes (MDS) [7] Global Expansion Strategy - The company emphasizes a dual approach of clinical and business development, with significant partnerships, including a major collaboration with Takeda for Nairike [8][9] - The company plans to list on NASDAQ in January 2025, marking a significant step in its global market strategy [8] Financial Performance - In the first half of 2025, the company reported revenues of 234 million yuan, with Nairike sales reaching 217 million yuan, a 93% increase year-on-year due to its inclusion in the national medical insurance directory [9][10] - The company has over 3 billion yuan in cash reserves, indicating strong financial health [10] Commercialization Strategy - The company has developed a short- and long-term commercialization plan for Nairike, partnering with established firms to enhance market penetration [10][11] - Following the launch of Lishengtuo, the company has signed agreements with major pharmaceutical distributors to expedite its market entry [10] Future Outlook - The company plans to expand its commercial team significantly, aiming for 400 members by 2026, to enhance its market presence in the hematology oncology sector [11] - The focus will remain on advancing key global clinical projects and integrating Lishengtuo into the medical insurance system [11]
亚盛医药董事长杨大俊：以持续创新筑根基 全球布局启新程